Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.38 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29014146 | 0.83 | MBTD1 (0.38) | SLC6A2SLC6A4SLC6A3SLC18A3SIGMAR1 | |
| SCHEMBL24646053 | 0.81 | SLC6A3 (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25474388 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3SLC6A9 | |
| SCHEMBL25474391 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3SLC6A9 | |
| SCHEMBL17609123 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3SLC18A3SIGMAR1 | |
| SCHEMBL23536155 | 0.78 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3SLC18A3SIGMAR1 | |
| SCHEMBL25324799 | 0.77 | FFAR1 (0.51) | SLC6A2SLC6A4SLC6A3IDO1 | |
| SCHEMBL4141018 | 0.77 | SLC18A3 (0.46) | SLC18A3SIGMAR1MBTD1L3MBTL3IDO1 | |
| SCHEMBL5858340 | 0.74 | IDO1 (0.43) | SLC6A2SLC6A4SLC6A3SLC18A3SIGMAR1 | |
| SCHEMBL7605334 | 0.74 | IDO1 (0.47) | SLC6A2SLC6A4SLC6A3SLC18A3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151037-A1 | GPR40 AGONISTS | KALLYOPE, INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115867536-A | GPR40 agonists | 卡尔优普公司 | 2023-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151037-A1 | GPR40 AGONISTS | GPR119, GPR65, GLP1R | SLC6A2 1148/4885SLC6A4 596/4885SLC6A3 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.